ProCE Banner Activity

Optimizing Management of CLL With BTK Inhibitors: A Pharmacist’s Perspective

Clinical Thought
How do you talk to patients with CLL about managing their disease with BTK inhibitors? Read my thoughts on how I use my interactions to educate patients about treatment options, planning for AEs, and improve outcomes.

Released: April 29, 2021

Expiration: April 28, 2022

Share

Faculty

Emily Bucholtz

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Emily Bucholtz, RPh

Pharmacist
Willamette Valley Cancer Institution
Eugene, Oregon

Emily Bucholtz, RPh, has no relevant conflicts of interest to report.